Human Immunodeficiency Virus (HIV): Overview, Transmission and Treatment
HIV is a retrovirus that attacks the immune system. This article explains its biology, stages of infection, transmission routes, diagnosis, treatment and prevention, and the distinction between HIV and AIDS.
Overview
Human immunodeficiency virus (HIV) is a virus that primarily infects cells of the human immune system. It belongs to the lentivirus subgroup, a type of retrovirus that carries its genetic information as RNA and uses reverse transcription to integrate into host DNA. Two main types are recognized: HIV-1, which is the most widespread globally, and the less common HIV-2, which is largely found in specific regions.
Image gallery
10 ImagesHow HIV affects the body
HIV targets immune cells, especially CD4+ T cells, which coordinate immune responses. Over time the virus reduces CD4 cell numbers and impairs immune function. When immune damage becomes severe, the person becomes vulnerable to opportunistic infections and certain cancers. The virus does not immediately cause the syndrome known as AIDS, but untreated HIV infection may progress to that stage.
Stages and symptoms
Infection typically follows a pattern: an initial acute phase with flu-like symptoms, a prolonged clinically latent phase that can last years, and eventually advanced immune deficiency if untreated. Many people are asymptomatic for long periods while still able to transmit the virus. Diagnosis and monitoring focus on antibody or antigen detection and measurement of viral load and CD4 counts.
Transmission and prevention
- Primary routes: unprotected sexual contact, exposure to infected blood (including shared needles), and mother-to-child transmission during pregnancy, childbirth or breastfeeding.
- HIV is not spread by casual contact, saliva, or insect bites.
- Prevention tools include condoms, sterile injection practices, screening of blood products, pre-exposure prophylaxis (PrEP), and timely antiretroviral treatment for people living with HIV to reduce transmission risk.
Diagnosis, treatment and outlook
Testing can detect HIV antibodies, antigens, or viral RNA. Modern antiretroviral therapy (ART) uses combinations of drugs to suppress viral replication, preserve immune function and prevent progression to AIDS. When adhered to, ART typically reduces viral load to undetectable levels, improving health and preventing most transmission. Research continues toward vaccines and long-term remission strategies, but there is currently no widely available cure.
History and notable distinctions
HIV was identified in the early 1980s in association with unusual clusters of infections. Since then, global public health responses have expanded testing, treatment and prevention programs. It is important to distinguish between HIV (the virus) and immune system consequences that together define AIDS: HIV is the causative agent, while AIDS is the advanced clinical condition resulting from prolonged immune failure. Awareness, regular testing and access to care remain central to reducing illness and transmission.
Structure and composition of the HI virus
HIV belongs to the complex retroviruses, i.e. in addition to the canonical retroviral genes gag, pol and env, the viruses possess further regulatory and accessory reading frames, namely in HIV-1 tat, rev, vif, vpu, vpr and nef.
The virus particle (virion) has a diameter of about 100 to 120 nanometers, which is above average for a virus, but significantly smaller than, for example, erythrocytes (diameter 7500 nanometers). HIV is surrounded by a lipid bilayer, which was separated from the human host cell during budding. Accordingly, various membrane proteins of the host cell are located in the viral envelope. Also embedded in this envelope are about 10 to 15 so-called spikes per virion, env-glycoprotein complexes of about ten nanometres in size; the density of the spikes is thus quite low, but there would be room for 73 ±25 of these projections on the surface of an HIV particle. An HIV spike consists of two subunits: Three molecules of the external surface glycoprotein gp120 are non-covalently bound to three molecules of the transmembrane envelope glycoprotein gp41. Gp120 is critical for binding of the virus to the CD4 receptors of target cells. Since the envelope of the HI virus originates from the host cell membrane, it also contains various host cell proteins, for example HLA class I and II molecules as well as adhesion proteins.
The matrix proteins p17 encoded by gag are associated with the inner side of the membrane. Inside the virion is the viral capsid, which is composed of the capsid proteins encoded by gag. The capsid protein p24 can be detected as an antigen in fourth generation HIV assays. In the capsid, associated with the nucleocapsid proteins encoded by gag, is the viral genome (9.2 kb) in the form of two copies of the single-stranded RNA. The nucleocapsid proteins have the function of protecting the RNA from degradation after entry into the host cell. Also located in the capsid are the enzymes reverse transcriptase (RT), integrase, and some of the accessory proteins. The protease is significantly involved in particle formation and is therefore found throughout the virus particle.
History
HIV is the name recommended by the International Committee on Taxonomy of Viruses (ICTV) in 1986. It replaces the former designations such as lymphadenopathy-associated virus (LAV), human T-cell leukemia virus III (HTLV-III) or AIDS-associated retrovirus (ARV).
HIV type 1 was first described in 1983 by Luc Montagnier and Françoise Barré-Sinoussi of the Institut Pasteur in Paris, and as early as June 1983 Der Spiegel covered HIV in its cover story ("Die tödliche Seuche Aids").
In the same issue of the journal Science, Robert Gallo, the head of the Tumor Virus Laboratory at the NIH in Bethesda, also published the discovery of a virus that he believed could cause AIDS. In that publication, however, he described the isolation of human T-cell leukemia virus type I (HTLV-1; shortly thereafter, also of HTLV-2) from AIDS patients, which happened to be present in his samples alongside the HI virus, and did not also isolate the HI virus until about a year later. In a press conference with the then Secretary of Health and Human Services of the United States, Margaret Heckler, he publicly announced on April 23, 1984, that AIDS was caused by a virus that he had discovered.
Both Montagnier and Gallo claimed first discovery. This was followed by years of litigation, which also involved the patent for the newly developed HIV test. In 1986, HIV-2 was discovered.
The two researchers Françoise Barré-Sinoussi and Luc Montagnier were awarded the Nobel Prize for Medicine in 2008 for the discovery of the HI virus. The fact that Gallo was not included in this award was met with criticism in part by the virology community.
In May 2005, an international team of researchers succeeded in proving for the first time that the origin of HIV lies in monkeys. The research team took 446 faecal samples from free-living chimpanzees in the wilderness of the central African country of Cameroon. Several samples showed antibodies against Simian Immunodeficiency Virus (SIV), the chimpanzee version of HIV, as the team published in the US journal Science. Twelve samples were almost identical to HIV-1 in humans. The team stressed that the antibodies had previously only been detected in chimpanzees in captivity. However, chimpanzees are not the original source of HIV. They are believed to have been infected with SIV or a precursor of this virus in other ape species in west-central Africa. Around the beginning of the 20th century, humans were infected for the first time with SIV, which subsequently mutated in their organisms into the AIDS-causing HIV. This means that the virus has already crossed the species barrier at least twice, from monkeys to apes and then to humans. How the virus was transmitted to humans is unclear. It is assumed that hunters who hunted and ate apes were infected with the virus for the first time, for example through minor open wounds.
Another thesis was that a vaccine against poliomyelitis (polio) in 1959 had been contaminated by monkeys carrying the virus (see also controversy over the origin of AIDS). According to this thesis, chimpanzee kidneys were used to propagate the vaccine in the former Belgian Congo and then hundreds of thousands of people were inoculated by oral vaccination, whereby SIV was transmitted to humans and mutated into HIV. However, an analysis of the mutations showed that there was a 95 percent probability that the origin of strain HIV-1 pre-dated 1930. In February 2000, a sample of the oral vaccines distributed was found and examined. It showed no traces of either HIV or SIV.
The oldest infected person whose HIV infection has been proven with certainty on the basis of blood samples comes from Belgian Congo and from the year 1959. In the initial publication on this serum sample, however, it was stated that the origin of the sample had not been clarified with certainty, so it is also possible that a person was infected for the first time in what was then French Equatorial Africa. A DNA paraffin sample of almost the same age from 1960, also from Belgian Congo, differs significantly genetically from the first sample, suggesting that HIV was present in Africa long before 1960. By means of statistical analyses (so-called molecular clock), the time window for the first appearance can be narrowed down with high probability to the years between 1902 and 1921. During this period, the African natives, who served as workers and carriers of raw materials, among other things, were treated against sleeping sickness by the Belgian colonial rulers in the Congo. For this purpose, syringes that had not been disinfected and were therefore infected with HIV were used for several people. In addition, rather poor medical and hygienic conditions were compounded by newly introduced diseases (including syphilis from Europe), which further weakened the population and made them vulnerable. The carrier columns could also have contributed to bringing the HI virus from the interior to the coast, so that it could be spread further from there.
When HIV first appeared in the USA, i.e. at the starting point of the AIDS pandemic, has long been the subject of research with varying, sometimes controversial results. As early as 1968, AIDS-like symptoms were observed in the patient Robert Rayford and later identified as HIV. However, it could not be conclusively proven that this was the HIV circulating today. According to a recent paper from 2016, the virus (HIV-1 subtype B) is estimated to have traveled from Africa to Haiti in 1967 and from there to the United States around 1971, demonstrating that Gaëtan Dugas, long thought to be Patient Zero, could not have been the first infected person in North America. The data refer to phylogenetic extrapolations. The earliest serological evidence is found in samples from San Francisco and New York City, both from 1978 onwards.
The theory that the AIDS pandemic was caused by a laboratory accident in the USA was created by the KGB in the course of Operation Infection and is classified as a conspiracy theory. In the 1980s, Jakob Segal developed a hypothesis in Berlin with a presumably scientific background, which also assumes a laboratory accident at Fort Detrick as the trigger of the AIDS pandemic, but which, in deviation from the KGB's representations, assumes genetic recombination from a Visna virus and HTLV-I as the artificial origin of HIV-1.
Questions and answers
Q: What is HIV?
A: HIV stands for Human immunodeficiency virus and is a type of Lentivirus which infects the human immune system.
Q: What kind of virus is HIV?
A: HIV is a retrovirus.
Q: What is the function of the human immune system that HIV infects?
A: The human immune system fights off infections.
Q: Can HIV cause AIDS?
A: Yes, HIV may cause AIDS.
Q: How does HIV kill the white blood cells?
A: HIV kills the white blood cells which a healthy body uses to fight diseases.
Q: What are the consequences of HIV killing the white blood cells which fight diseases?
A: The consequences of HIV killing the white blood cells are that the body becomes more vulnerable to infections and diseases.
Q: Is there a cure for HIV?
A: Currently, there is no cure for HIV, but treatment can help manage it and prevent it from progressing to AIDS.
Author
AlegsaOnline.com Human Immunodeficiency Virus (HIV): Overview, Transmission and Treatment Leandro Alegsa
URL: https://en.alegsaonline.com/art/44555
Sources
- avert.org : "Can I get AIDS from...?"
- cdc.gov : "Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services"
- pubmed.ncbi.nlm.nih.gov : 15660015
- ncbi.nlm.nih.gov : "Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART"
- doi.org : 10.1097/QAD.0b013e3283372d90
- pubmed.ncbi.nlm.nih.gov : 20139750
- pubmed.ncbi.nlm.nih.gov : 2240875
- doi.org : 10.1056/NEJMe048128
- pubmed.ncbi.nlm.nih.gov : 15247337
- pubmed.ncbi.nlm.nih.gov : 7552482
- doi.org : 10.1016/S0002-9343(97)89441-7
- pubmed.ncbi.nlm.nih.gov : 9845490
- doi.org : 10.1016/S1473-3099(09)70021-0
- pubmed.ncbi.nlm.nih.gov : 19179227





